Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation

被引:5
作者
Gressner, Olav
Popp, Henning
Mey, Ulrich
Friedrichs, Nicolaus [2 ]
Strehl, John
Sauerbruch, Tilman
Schmidt-Wolf, Ingo G. H.
Gorschlueter, Marcus [1 ]
机构
[1] Univ Klinikum Bonn, Med Klin & Poliklin 1, Dept Internal Med 1, D-53105 Bonn, Germany
[2] Univ Klinikum Bonn, Inst Pathol, D-53105 Bonn, Germany
来源
ONKOLOGIE | 2008年 / 31卷 / 8-9期
关键词
small cell lung cancer; prognosis; chemotherapy; long-term survival;
D O I
10.1159/000142396
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Small cell lung cancer (SCLC) results in death within 1-2 months if left untreated. Although therapeutic standards only comprise first- and second-line chemotherapy due to poor prognosis, a subset of patients may warrant a trial of further chemotherapy, as demonstrated in the following case. Case Report: We present a 52-year-old man with confirmed anaplastic SCLC who survived 10 years while receiving 9 lines of chemotherapy including high-dose chemotherapy. Thoracic radiation, afterloading and radionuclide therapy supplemented the therapeutic management. Remarkably, he had two very long remission periods following topotecan. Conclusion: This case indicates that frequently repeated chemotherapy beyond second-line treatment in a subset of patients with limited-disease SCLC may result in long-term survival, even without ever achieving a complete remission. Close surveillance of responsiveness and appropriate in-time cytostatic treatment is proposed in the management of patients with SCLC who remain in good performance.
引用
收藏
页码:469 / 472
页数:4
相关论文
共 25 条
[1]   FDG-PET: An important tool in the diagnosis of lung cancer [J].
Abenhardt, Wolfgang .
ONKOLOGIE, 2007, 30 (07) :352-352
[2]   LONG-TERM SURVIVAL AND TOXICITY IN SMALL-CELL LUNG-CANCER - EXPANDED SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LIVINGSTON, RB .
CHEST, 1991, 99 (06) :1425-1432
[3]   PROGNOSTIC INFLUENCE OF TNM STAGING AND LDH LEVELS IN SMALL CELL-CARCINOMA OF THE LUNG (SCCL) [J].
BYHARDT, RW ;
HARTZ, A ;
LIBNOCH, JA ;
HANSEN, R ;
COX, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (05) :771-777
[4]  
CASTELLANO DE, 2003, P AN M AM SOC CLIN, V22, P674
[5]   Third-line chemotherapy for small cell lung cancer [J].
de Jong, Wouter K. ;
ten Hacken, Nick H. T. ;
Groen, Harry J. M. .
LUNG CANCER, 2006, 52 (03) :339-342
[6]   Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Bentzen, SM ;
Minken, A ;
Wanders, R ;
Lutgens, L ;
Hochstenbag, M ;
Boersma, L ;
Wouters, B ;
Lammering, G ;
Vansteenkiste, J ;
Lambin, P .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063
[7]  
Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048
[8]   Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer [J].
Fried, DB ;
Morris, DE ;
Poole, C ;
Rosenman, JG ;
Halle, JS ;
Detterbeck, FC ;
Hensing, TA ;
Socinski, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4837-4845
[9]   Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study [J].
Hanna, NH ;
Sandler, AB ;
Loehrer, PJ ;
Ansari, R ;
Jung, SH ;
Lane, K ;
Einhorn, LH .
ANNALS OF ONCOLOGY, 2002, 13 (01) :95-102
[10]   Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression [J].
Hsia, TC ;
Lin, CC ;
Wang, JJ ;
Ho, ST ;
Kao, A .
LUNG, 2002, 180 (03) :173-179